3-O-β-D-Glucopyranoside-betulinic acid an anti-cancer agent compound, was prepared through enzymatic reaction of betulinic acid and glucose in organic solvent which gave 87.5% yield. Its spectroscopic data is now reported. Interestingly, 3-O-β-D-glucopyranoside-betulinic acid also showed strong activity against cultured Human breast cancer (MCF-7), Human T-promyelocytic leukemia (HL-60) and Mouse embryonic fibroblast cancer (3T3) with IC 50 values of 8.5, 8.4 and 2.75µg/ml respectively. However, it was found to have moderate activity against Human cervical carcinoma cancer (HeLa) cell line with IC 50 value of 12.0µg/ml.
Introduction
Natural products have been used for combating human diseases for thousands of years since they exhibit biological properties which can be exploited for medical applications (Newman et al., 2003) . Synthetic transformations of these natural compounds for the developing biologically active agents have become the basis of the actively advancing scientific direction of perfect organic synthesis and medical chemistry (Tolstikov et al., 2005) . The greatest attention of researchers is attracted by native compounds with reliably established biological activity.
Betulinic acid (1) in particular, is a natural agent isolated from many plants and it was first described to induced apoptosis in neuro ectodermal tumour cells (Pisha et al., 1995) . Betulinic acid belongs to the naturally occuring pentacyclic lupane-type triterpenoids which was reported to posseses various pharmacological activities which include anti-cancer, anti-HIV, anti-malarial, anti-inflammatory and anti-fungal (Recio et al., 2005; Yuan et al., 2008; Mukherjee et al., 1997; Hanne et al., 2004 ). However, the major hinderance for the future clinical development of betulinic acid and its analogs resides in its weak hydrosolubility in aqueous media like serum, blood and non-polar solvents like water used for bioassays (Gauthier et al., 2006) .
One of the strategies to increase betulinic acid hydrosolubility is by the synthesis of its glycoside derivatives. Furthermore, the bioactivity of betulinic acid, in some cases can be improved upon the addition of sugar moiety at either C-3 or C-28 or both. Some natural and synthetic betulinic acid glycosides were also reported in the literature (Hamisu et al., 2012) . Example, 3-O-β-D-glucopyranoside-betulinic acid (2) was synthesised by chemical reactions (Gauthier et al., 2006) and shown some bioactivities (Recio et al., 1995) . Their synthesis however seems to be difficult in purification procedual. Thus, in connection with our continious effort on the enzymatic reaction of betulinic acid we now report the preparation of 3-O-β-D-glucopyranoside-betulinic acid (2) by enzymatic glucosidation of betulinic acid (1) and glucose using Novozyme® 435 in organic solvent. Interestingly, it was observed that the reaction was clean and simple, and gave high yield of product. The evaluation of this compound toward some cancer cell lines was also reported herein. The structures of compound (1) and (2) were shown in Figure 1 . 
Experiment and Materials
Betulinic acid was donated by Prof.(Dr) Faujan B.H.A, glucose was purchased from Merck, Germany, Novozyme® 435 was purchased from Novo Nordisk A/S (Denmark), t-butanol, hexane, ethylethanoate, Dimethylsulfoxide (DMSO) and Microculture Tetrazolium salt (MTT) were purchased from Merck, Germany. It is important to note that all chemicals used in this work were of analytical reagents grade. Nevertheless, they are also pure and distilled. The cancer cell lines HL-60, MCF-7, HeLa; and 3T3 were supplied by Institute of Bioscience (IBS), UPM and were purchased from American Type Cell Culture Collection (ATCC), USA.
Preparation of 3-O-β-D-Glucopyranoside-betulinic Acid (2)
This compound was prepared using betulinic acid (22.8mg, 0.5x10 -1 mmol) and glucose (18.0mg, 1.0x10 -1 mmol) dissolved in t-butanol (10 ml). Novozyme® 435 (180mg) was then added and the reaction mixture was incubated on a water bath shaker (Memmert WB 14, Germany) for 30 h, at 55.0 o C and 150 rpm. The progress of the reaction was monitored using thin layer chromatography (TLC) with hexane and ethylacetate as the eluent (8:2 v/v). The enzymes was then removed by filtration. Removal of the solvent under reduce pressure gave a yellowish solid. The product was then purified through celite flash column chromatography followed by crystallized from t-butanol to give the pure material of the desired product as light yellow crystal, 0.028g (87.5 %). It melted at of 235.5-238.2 o C (uncorrected) (literature 234-236 o C, Gauthier et al., 2006) .
The NMR spectra of the compound was recorded with Varian Unity Inova 400 NMR spectrometer operating at a resonance frequency of 499.89 MHz for 1 HNMR spectra and 125.71MHz for 13 C-NMR spectra. The mass spectrum was recorded using Shimadzu, QP5050, Japan.
Cytotoxic activity of the product was evaluated against HL-60, Cancer cell line), MCF-7 Cancer cell lines (Human breast cancer), HeLa Cancer cell line (Human cervical carcinoma cancer) and 3T3 cell line (Mouse embryonic fibroblast cancer) respectively. All these cell lines were supplied by Institute BioScience (IBS) University Putra Malaysia, and were purchased from American Type Cell Culture Collection (ATCC), USA. Culture were maintained according to Harish et al. (2010) as monolayers in RPMI-1640 supplemented with 10% heat inactivated fetal bovine serum and 1% penicillin/steptomycin at 37 o C in a humidified atmosphere using 5% carbon(IV)oxide (CO 2 ).
The cytotoxic activity of the product was evaluated using calorimetric Microculture Tetrazolium salt assay (MTT). Exponentially the growing cells were plated in 96-well microplates (Coster Corning Inc.) at a density of 5x10 3 cells per well in 100µL of the culture medium and these were allowed to adhere for 72 h before treatment in order to prevent confluence (Harish et al., 2010) . After 72 h of incubation, the fractions of the surviving cells were measured relative to the untreated cell population by MTT assay. A volume of 20ml of MTT salt (5mg/ml) in phosphate buffer solution was added to each microtiter well and incubated again for 3-4 h. 100µl of Dimethyl sulfoxide (DMSO) was then added to dissolve the remaining MTT formazan crystal by pippeting up and down 10-20 times. The plates was left at room temperature for 15-30 minutes. The optical density (OD) was measured on an ELIZA microplate reader at 570 nm and the percentage of cell viability was calculated using the equation:
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A plot of percentage cell viability against the concentration of the drug gives a measure of the cutotoxicity. The cytotoxic index used was IC 50 , the drug concentration lethal to 50% of the tumor cells as calculated from the plate.
Results and Discussion
The product obtained after purification appeared to be a light yellow crystal (87.5%) with a melting point of 235.5-238. H-NMR spectra of 3-O-β-D-Glucopyranoside-betulinic acid indicates the presence of 6 methyl groups (each singlets) at δ 0.85, 1.03, 1.10, 1.08, 1.25 and 1.82 respectively (each 3H, assigned for 23-CH 3 , 24-CH 3 , 25-CH 3 , 26-CH 3 , 27-CH 3 and 30-CH 3 respectively). The signal at δ 3.48 (1H, dd) was due to the hydrogen proton assigned at C-3 position. The presence of two hydrogens at C-29 position was confirmed by the presence of proton signals at δ 4.80 (1H,s) and δ 4.97 (1H,s). The doublet proton signal at δ 4.58 (1H, d) was assigned as the proton attached to the carbon bearing at position C-3. The signal at δ 3.48 (1H, m) was due to the hydrogen at C-19 position. The 13 C-NMR of of 3-O-β-D-Glucopyranoside-betulinic acid showed the presence of signal at δ 78.9, which was assigned to C-3 of the compound. The signal at 151.4 ppm and 110.1 ppm was due to the carbon double bond between C-20 and C-29 respectively. The 13 C-NMR of the compound also shows a carboxyl carbon signal at δ 178.9 ppm assigned as C-28 (COOH).
The structure of the expected product was further comfirmed using HMBC, HSQC and COSY spectrum. The selected HMBC (Figure 1 Vol. 4, No. 5; Bioactivity Studies Based on IC 50 values, compounds with IC 50 < 10 µg/ml were considered to be strongly active, those with IC 50 ranging from 10-30 µg/ml were considered to be moderately active while compounds with IC 50 > 30 µg/ml were considered as weakly active (Ahmad et al., 2010a; 2010b) . Our bioactivity results conducted, betulinic acid (1) showed high activity against cultured human breast cancer (MCF-7), human T-promyeloctic leukaemia (HL-60), and human cervical carcinoma cancer (HeLa) cell lines with IC 50 values 0.8, 4.4 and 4.8 µg/ml respectively, however, betulinic acid was shown to be highly inactive against mouse embryonic fibroblast normal cell line (3T3) with IC 50 value > 30 µg/ml. In contrast, 3-O-β-D-glucopyranoside betulinic acid still showed strong activity against cultured human breast cancer (MCF-7), human T-promyeloctic leukaemia (HL-60) and mouse embryonic fibroblast normal cell line (3T3) with IC 50 values 8.5, 8.4 and 2.75 µg/ml respectively, but it was found to have moderate activity against human cervical carcinoma cancer (HeLa) cell line with IC 50 value 12.0 µg/ml. (Table 2 ). Since the introduction of glucose in betulinic acid reduced their cytotoxic activity, it may due to the fact that the glycoside is having higher molecular weight thus cannot pass through the cell membrane completely, although the introduction of sugar in betulinic acid molecule was expected to increases its hydrosolubility properties. 
Conclusion
In conclusion, 3-O-β-D-glucopyranoside-betulinic acid was prepared and characterized using spectroscopic data.
